Affinage

OPCML

Opioid-binding protein/cell adhesion molecule · UniProt Q14982

Length
345 aa
Mass
38.0 kDa
Annotated
2026-06-10
53 papers in source corpus 20 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

OPCML (OBCAM) is a GPI-anchored, lipid raft-resident IgLON family cell-surface adhesion molecule that acts as a broad tumor suppressor and a regulator of synaptic structure (PMID:12819783, PMID:8965653, PMID:8740443, PMID:22585860). Its three-immunoglobulin-like-domain ectodomain adopts an extended arrangement and homodimerizes through membrane-distal contacts; clinical missense variants mapped onto this structure impair RTK binding, anchorage-independent growth, migration, invasion, and tumor growth (PMID:31316070). As a cell-surface repressor-adaptor, OPCML binds the extracellular domains of a defined repertoire of receptor tyrosine kinases (EPHA2, FGFR1, FGFR3, HER2, HER4), redirecting them through non-clathrin/caveolin-1 endocytosis toward polyubiquitination-dependent proteasomal degradation (PMID:22585860). It additionally captures ligand-activated AXL into cholesterol-rich domains where it juxtaposes phospho-AXL with the lipid-domain phosphatase PTPRG, driving AXL dephosphorylation and blocking downstream ERK signaling, EMT, migration, and invasion (PMID:29907679), and its binding to HER2 disrupts HER2-EGFR heterodimers to suppress EGFR signaling (PMID:28775148). OPCML expression is epigenetically silenced in cancer by oncogenic RAS-driven CpG island promoter hypermethylation (PMID:12819783, PMID:16384911). In the nervous system, OPCML localizes to postsynaptic dendritic spines within lipid rafts and undergoes activity-dependent, cholesterol-dependent internalization to promote synaptogenesis (PMID:17658490, PMID:12850579); it interacts with EphB2 to regulate cofilin phosphorylation and F-actin dynamics for spine maturation (PMID:31577955) and shapes glutamatergic transmission through postsynaptic AMPA/NMDA receptor function (PMID:39420375).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 1996 High

    Establishing how OPCML attaches to the cell surface defined it as a GPI-anchored, glycosylated membrane protein rather than a transmembrane receptor, framing all later interpretations of its raft residence and adaptor function.

    Evidence PI-PLC release and N-glycanase digestion in transfected cells and native bovine brain membranes

    PMID:8740443 PMID:8965653

    Open questions at the time
    • Does not address signaling output or binding partners
    • No structural detail of the ectodomain
  2. 1996 Medium

    A closely related IgLON ortholog (GP55) was shown to inhibit neurite outgrowth and to be reversible by antibody, providing the first functional readout that IgLON family members act as cell-surface modulators of neuronal growth.

    Evidence Substrate-bound neurite outgrowth inhibition with antibody reversal in DRG neurons (chick ortholog)

    PMID:9004047

    Open questions at the time
    • Chick ortholog, not direct OPCML evidence
    • Molecular partner mediating inhibition not identified
  3. 2003 High

    OPCML was established as a tumor suppressor in epithelial ovarian cancer, answering whether its frequent loss is causal by combining allele loss, methylation, a loss-of-function mutation, and functional rescue.

    Evidence LOH, methylation-specific PCR, somatic mutation analysis, and ectopic expression with in vitro and in vivo tumor growth assays

    PMID:12819783

    Open questions at the time
    • Molecular mechanism of suppression unresolved at this stage
    • Binding partners not yet identified
  4. 2003 Medium

    Parallel neuronal work showed OPCML resides postsynaptically in dendritic lipid rafts and engages other IgLONs, indicating a synaptic adhesion role distinct from its tumor context.

    Evidence EM/immunohistochemistry, cross-linker binding and IP with Kilon, live-cell surface labeling and detergent raft fractionation

    PMID:12617969 PMID:12850579

    Open questions at the time
    • Functional consequence of synaptic localization not yet tested
    • Homophilic vs heterophilic binding stoichiometry unresolved
  5. 2006 Medium

    Lentiviral restoration of OPCML demonstrated cell-cycle arrest, increased surface adhesion, and suppressed tumorigenicity, refining the tumor-suppressor phenotype to specific cellular outputs.

    Evidence Lentiviral transduction, aggregation assay, flow cytometry, proliferation and xenograft assays in ovarian cancer cells

    PMID:16762191

    Open questions at the time
    • Mechanism linking adhesion to cell-cycle arrest not defined
    • Effect restricted to a subset of lines
  6. 2006 High

    The cause of OPCML silencing was traced to oncogenic RAS, showing that elevated RAS signaling drives CpG island promoter hypermethylation and that this is reversible.

    Evidence Methylation-sensitive PCR, 5-aza demethylation, and HRASV12 siRNA rescue restoring expression

    PMID:16384911

    Open questions at the time
    • Intermediate methyltransferase machinery not identified
    • Whether other oncogenes converge on the same promoter unknown
  7. 2007 High

    Loss- and gain-of-function in hippocampal neurons established OPCML as a positive regulator of synaptogenesis and revealed activity-dependent, cholesterol-dependent internalization, linking its raft residence to a dynamic trafficking cycle.

    Evidence Antibody blocking, antisense knockdown, overexpression, activity stimulation, and filipin internalization assay

    PMID:17658490

    Open questions at the time
    • Downstream effectors of synaptogenesis not defined here
    • Receptor partner mediating the effect unknown at this stage
  8. 2009 Medium

    OPCML was shown to control astrocyte proliferation and size in a clustering-dependent manner, extending its cell-surface signaling role beyond neurons and tumor cells.

    Evidence Anti-OBCAM IgG vs Fab comparison, overexpression, Ki-67, and in vivo brain injury model

    PMID:19943852

    Open questions at the time
    • Signaling pathway downstream of clustering not defined
    • Single-lab phenotype
  9. 2012 High

    The core molecular mechanism of tumor suppression was defined: OPCML acts as a cell-surface repressor-adaptor binding extracellular domains of specific RTKs and routing them through non-clathrin/caveolin-1 endocytosis to proteasomal degradation.

    Evidence Co-IP, clathrin vs non-clathrin trafficking assays, ubiquitination and proteasome inhibition, and recombinant domain 1-3 rescue in vitro and in vivo

    PMID:22585860

    Open questions at the time
    • How specificity for this RTK repertoire is encoded not resolved
    • Adaptor proteins linking OPCML to the endocytic machinery unidentified
  10. 2015 Medium

    Restored OPCML was shown to inhibit TGFβ-Smad signaling and reverse partial EMT in colorectal cancer, generalizing its tumor-suppressor reach beyond ovarian tissue and beyond RTK degradation.

    Evidence Ectopic expression, Smad phosphorylation blotting, EMT marker and invasion assays, nuclear receptor association

    PMID:26175934

    Open questions at the time
    • Mechanism connecting a GPI-anchored protein to Smad signaling unclear
    • Functional role of ERRα/RORα association untested
  11. 2017 Medium

    OPCML was shown to bind HER2 but not EGFR and to disrupt HER2-EGFR heterodimers, providing a distinct mechanism (heterodimer disruption) that sensitizes cells to EGFR/HER2 inhibitors.

    Evidence Co-IP, heterodimerization assay, and lapatinib/erlotinib viability assays with clinical correlation

    PMID:28775148

    Open questions at the time
    • Reciprocal validation of heterodimer disruption limited
    • Generalizability across HER2-driven tumors not tested
  12. 2018 High

    A phosphatase-coupling mechanism was established: OPCML preferentially binds ligand-activated AXL, concentrates it in cholesterol-rich domains, and juxtaposes it with PTPRG for dephosphorylation, blocking AXL-driven cMET/EGFR transactivation and EMT.

    Evidence Reciprocal Co-IP, lipid domain fractionation, PTPRG proximity/activity assays, ERK and migration/invasion assays, and in vivo AXL-inhibitor combination

    PMID:29907679

    Open questions at the time
    • Whether the PTPRG-coupling mode applies to the other RTK targets unknown
    • Direct ternary complex structure not resolved
  13. 2019 High

    The OPCML crystal structure and structure-guided mutagenesis defined its three-Ig-domain architecture, membrane-distal homodimerization, and showed that clinical missense variants abolish RTK binding and tumor-suppressor activity, mechanistically linking structure to function.

    Evidence X-ray crystallography at 2.65 Å with mutagenesis, anchorage-independent growth, Co-IP, migration/invasion, and in vivo tumor assays

    PMID:31316070

    Open questions at the time
    • Co-crystal with an RTK partner not obtained
    • Functional role of the homodimer interface in vivo not dissected
  14. 2019 High

    Genetic knockout connected OPCML to a defined synaptic signaling axis, showing it interacts with EphB2 to regulate cofilin phosphorylation and F-actin dynamics for spine maturation, with pharmacological rescue.

    Evidence Co-IP, Opcml knockout mice, phospho-cofilin blotting, F-actin and spine analyses, behavior, and aripiprazole rescue

    PMID:31577955

    Open questions at the time
    • How EphB2 binding couples to cofilin not mechanistically resolved
    • Relationship to its RTK-degradation role in tumors unexplored
  15. 2021 Medium

    In cholangiocarcinoma, restored OPCML was shown to act through AXL/STAT3 inactivation and Rho GTPase downregulation, reinforcing AXL as a recurrent target across tumor types.

    Evidence Ectopic expression with AXL/STAT3 blotting, Rho GTPase activity, and proliferation/migration/invasion assays

    PMID:34697068

    Open questions at the time
    • Direct OPCML-AXL binding not re-demonstrated in this context
    • Link from AXL to Rho GTPases not mechanistically dissected
  16. 2022 Medium

    A transcriptional regulator of OPCML was identified, showing that GPBAR1 activation drives nuclear RAD21 to upregulate Opcml transcription and protect neurites in a Parkinson's model, placing OPCML downstream of a defined signaling-to-transcription axis.

    Evidence DA-neuron Gpbar1 knockdown, INT-777 activation, RAD21 nuclear fractionation, and synapse morphometry in mice

    PMID:36152741

    Open questions at the time
    • Direct RAD21 binding to the Opcml promoter not shown
    • Whether this regulatory axis operates in non-dopaminergic tissues unknown
  17. 2024 Medium

    Electrophysiology in knockout mice defined the functional synaptic consequence of OPCML loss as impaired glutamatergic transmission via postsynaptic AMPA/NMDA receptor dysfunction with disrupted E/I balance.

    Evidence Whole-cell patch clamp, AMPAR/NMDAR current analysis, and aripiprazole rescue in Opcml knockout mice

    PMID:39420375

    Open questions at the time
    • Molecular link between OPCML and receptor function not defined here
    • Single-lab electrophysiology
  18. 2025 Medium

    Proximity labeling identified OPCML as a direct binder of the AMPAR extracellular N-terminal domain during LTP, offering a candidate molecular basis for its control of glutamatergic transmission.

    Evidence Surface-restricted APEX2 proximity labeling, BioSITe proteomics, and direct OBCAM-AMPAR NTD binding assay (preprint)

    PMID:bio_10.1101_2025.07.11.664166

    Open questions at the time
    • Preprint, not peer-reviewed
    • Functional consequence of the NTD interaction on receptor trafficking not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How OPCML achieves target specificity — selecting particular RTKs and AMPARs, and choosing between degradation, phosphatase-coupling, and heterodimer-disruption outcomes — remains unresolved.
  • No co-structure of OPCML with any RTK or AMPAR partner
  • Adaptors linking OPCML to endocytic/degradation machinery unidentified
  • Unifying principle across its tumor and neuronal roles not established

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098631 cell adhesion mediator activity 4 GO:0060090 molecular adaptor activity 3 GO:0098772 molecular function regulator activity 3
Localization
GO:0005886 plasma membrane 4
Pathway
R-HSA-112316 Neuronal System 3 R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 2
Partners
AXLEPHA2EPHB2FGFR1GRIA1HER2PTPRG

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 OPCML (OBCAM) is a GPI-anchored IgLON family cell adhesion molecule that is somatically inactivated in epithelial ovarian cancer by allele loss and CpG island methylation; a somatic missense mutation showed loss of function, and restored expression suppressed tumor growth in vitro and in vivo, establishing tumor suppressor function. Loss of heterozygosity analysis, methylation-specific PCR, ectopic expression with in vitro and in vivo tumor growth assays, somatic missense mutation functional analysis Nature genetics High 12819783
2003 OBCAM (OPCML) is localized postsynaptically at dendritic and somatic synapses in adult cerebral cortex and hippocampus, and interacts both heterophilically and homophilically with the related IgLON family member Kilon, as demonstrated by cross-linker binding analysis and immunoprecipitation. Electron microscopy, immunohistochemistry, cross-linker binding analysis, immunoprecipitation Neuroscience Medium 12617969
2012 OPCML functions as a cell-surface repressor-adaptor that negatively regulates a specific repertoire of receptor tyrosine kinases (EPHA2, FGFR1, FGFR3, HER2, HER4) in ovarian cancer by binding their extracellular domains, redirecting trafficking via non-clathrin/caveolin-1-associated endocytosis, and promoting polyubiquitination-dependent proteasomal degradation. Recombinant OPCML domains 1–3 recapitulate this mechanism in vitro and in vivo. Co-immunoprecipitation, trafficking assays (clathrin vs. non-clathrin endocytosis), ubiquitination assays, proteasome inhibitor experiments, in vitro and in vivo (murine intraperitoneal) tumor growth assays with recombinant protein Cancer discovery High 22585860
2007 OBCAM (OPCML) is localized at postsynaptic spines in hippocampal neurons; inhibition of OBCAM function with specific antibody significantly decreased synapse number on dendrites, antisense knockdown impaired synapse formation, and overexpression augmented synapse formation, establishing a role in synaptogenesis. Activity-dependent internalization of OBCAM occurs via a lipid raft/cholesterol-dependent (filipin-sensitive) pathway. Immunofluorescence microscopy, antibody function-blocking, antisense oligodeoxynucleotide knockdown, plasmid overexpression, 4-aminopyridine neuronal activity stimulation, filipin treatment internalization assay Brain research High 17658490
2005 Oncogenic RAS (HRASV12) directly mediates epigenetic silencing of OPCML by promoting CpG island promoter hypermethylation; siRNA knockdown of HRASV12 reversed OPCML promoter methylation and restored expression, demonstrating that elevated RAS signaling drives OPCML epigenetic inactivation. Methylation-sensitive PCR, 5-aza-2'-deoxycytidine demethylation, stable siRNA knockdown of HRASV12, RT-PCR for OPCML re-expression FASEB journal High 16384911
2018 OPCML directly interacts with the activated RTK AXL (preferentially when AXL is bound by its ligand Gas6), causing AXL to accumulate in cholesterol-rich lipid domains where OPCML resides. There, OPCML brings phospho-AXL into proximity with the lipid domain-restricted phosphatase PTPRG, which dephosphorylates AXL, preventing AXL-mediated transactivation of cMET and EGFR, inhibiting sustained phospho-ERK signaling, Slug induction, EMT, cell migration, and invasion. Co-immunoprecipitation, lipid domain fractionation, phosphatase (PTPRG) proximity/activity assays, ERK signaling assays, migration/invasion assays, in vivo AXL inhibitor (R428) combination experiments EMBO reports High 29907679
2019 X-ray crystal structure of OPCML solved to 2.65 Å resolution reveals an extended arrangement of three immunoglobulin-like domains and homodimerization via contacts between membrane-distal domains. Somatic missense mutations from tumor databases were shown to impair anchorage-independent growth, interaction with activated RTKs, migration, invasion in vitro, and tumor growth in vivo. X-ray crystallography, structure-guided mutagenesis of clinical missense variants, anchorage-independent growth assays, Co-IP with RTKs, migration/invasion assays, in vivo tumor growth assays Nature communications High 31316070
2019 OPCML interacts with EphB2 in hippocampal neurons and controls spine stability by regulating the ephrin-EphB2-cofilin signaling pathway. Opcml ablation in mice reduces phosphorylated cofilin levels and dysregulates F-actin dynamics, disturbing spine maturation; aripiprazole partially restores behavior and phospho-cofilin levels. Co-immunoprecipitation (OPCML-EphB2 interaction), Opcml knockout mouse model, phospho-cofilin immunoblotting, F-actin dynamics assays, spine morphology analysis, behavioral testing (cognitive, sensorimotor gating), pharmacological rescue with aripiprazole Cell reports High 31577955
2017 OPCML interacts with HER2 but not EGFR; this interaction disrupts HER2-EGFR heterodimer formation and sensitizes HER2-expressing ovarian and breast cancer cells to the EGFR/HER2 inhibitors lapatinib and erlotinib, demonstrating that OPCML-HER2 binding indirectly suppresses EGFR signaling through heterodimer disruption. Co-immunoprecipitation (OPCML-HER2 interaction), HER2-EGFR heterodimerization assay, cell viability assays with lapatinib/erlotinib, in vitro and clinical correlation Molecular cancer therapeutics Medium 28775148
2015 Restored OPCML expression in colorectal cancer cells inhibits TGFβ-Smad signaling, reverses a partial epithelial-to-mesenchymal transition (EMT), and inhibits cell migration and invasion; OPCML expression was also found to be associated with the nuclear receptors ERRα and RORα. Ectopic OPCML expression, Smad phosphorylation western blotting, EMT marker analysis, migration/invasion assays, nuclear receptor association assays American journal of cancer research Medium 26175934
1996 OBCAM (OPCML) is linked to the cell membrane via a glycosylphosphatidylinositol (GPI) anchor, demonstrated by release from the membrane upon treatment with phosphatidylinositol-specific phospholipase C (PI-PLC) in transfected cells and in bovine brain membranes. PI-PLC treatment of transfected Cos1 cells and bovine brain P2 membranes, immunoblotting, N-glycanase digestion showing N-glycosylation Brain research. Molecular brain research / Neurochemistry international High 8740443 8965653
1996 GP55 (a chick homolog closely related to OBCAM/OPCML) inhibits neurite outgrowth from dorsal root ganglion neurons when presented as a substrate, and an antiserum against it reverses this inhibition, establishing that the IgLON family members can function as inhibitors of neurite outgrowth. Substrate-bound neurite outgrowth inhibition assay, antibody reversal assay, peptide sequencing, PCR cloning with homology to OBCAM Journal of cell science Medium 9004047
2009 OBCAM (OPCML) in astrocytes is expressed prominently at filopodia and cellular processes and controls astrocyte proliferation and cell size; antibody-induced clustering of OBCAM (but not Fab fragment treatment) promoted astrocyte proliferation, and OBCAM overexpression increased astrocyte cell size. OBCAM expression is upregulated on reactive astrocytes after brain injury in vivo. Confocal microscopy, anti-OBCAM IgG vs. Fab fragment treatment, OBCAM overexpression, Ki-67 proliferation marker, in vivo brain injury model Journal of neurochemistry Medium 19943852
2003 OBCAM (OPCML) is efficiently targeted to the dendritic surface of polarized cortical and hippocampal neurons, resides in lipid rafts (resistant to Triton X-100 extraction at 4°C and released by PI-PLC), and shows surface localization preferentially on dendrites compared to somata. Live-cell immunofluorescence (pre-fixation antibody labeling), PI-PLC treatment, detergent fractionation (Triton X-100 raft isolation), double labeling with synapsin I and MAP2 Brain research Medium 12850579
2021 Ectopic OPCML expression in cholangiocarcinoma cells inhibits proliferation by inducing apoptosis via inactivation of AXL/STAT3 signaling, and suppresses migration and invasion by downregulating Rho GTPases (RHOA, RAC1, CDC42). Ectopic OPCML expression (pcDNA3.1 vector), AXL/STAT3 phosphorylation western blotting, Rho GTPase activity assays, proliferation, migration, and invasion assays Cancer genomics & proteomics Medium 34697068
2022 GPBAR1 activation increases OPCML expression in dopaminergic neurons by promoting nuclear localization of the cohesin subunit RAD21, which in turn upregulates Opcml transcription, thereby protecting neurites and synapses in a Parkinson's disease model. This establishes RAD21 as a transcriptional regulator upstream of OPCML. DA neuron-specific Gpbar1 knockdown in mice, central GPBAR1 activation with INT-777, RAD21 nuclear fractionation/localization, OPCML expression measurement, neurite/synapse morphometry, behavioral assays Pharmacological research Medium 36152741
2024 Opcml deficiency in mice leads to decreased neuronal excitability and impaired glutamatergic synaptic transmission in hippocampal CA1 pyramidal neurons, specifically via postsynaptic AMPA/NMDA receptor dysfunction, resulting in disturbed excitatory/inhibitory balance. Aripiprazole rescued impaired glutamatergic transmission alongside behavioral improvement. Whole-cell patch clamp recordings in Opcml knockout mice, AMPAR/NMDAR current analysis, E/I balance measurements, pharmacological rescue with aripiprazole Molecular brain Medium 39420375
2006 Lentiviral expression of OPCML in ovarian cancer cell line A2780 increased cell-surface adhesion in all tested cell lines, arrested A2780 cells in G0/G1, reduced proliferation, and markedly suppressed tumorigenicity in nude mice, while having no effect on the OCC1 or normal CD1 mouse ovarian surface epithelial cells. Lentiviral OPCML transduction, cell aggregation assay, flow cytometry cell cycle analysis, CCK-8/proliferation assay, nude mouse xenograft tumorigenicity assay Zhonghua fu chan ke za zhi Medium 16762191
2025 OBCAM (OPCML) directly interacts with the extracellular N-terminal domain (NTD) of AMPA-type glutamate receptors (AMPARs), as identified by surface-restricted APEX2 proximity labeling during chemical LTP induction in cultured neurons; OBCAM was among four IgLON family members enriched in the AMPAR extracellular interactome after cLTP. Surface-restricted APEX2 proximity labeling, BioSITe-based proteomics, direct binding assay between OBCAM and AMPAR NTD bioRxivpreprint Medium bio_10.1101_2025.07.11.664166

Source papers

Stage 0 corpus · 53 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nature genetics 154 12819783
2008 OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PloS one 96 18714356
2003 Biochemical and ultrastructural analyses of IgLON cell adhesion molecules, Kilon and OBCAM in the rat brain. Neuroscience 63 12617969
2007 Expression of cellular adhesion molecule 'OPCML' is down-regulated in gliomas and other brain tumours. Neuropathology and applied neurobiology 52 17239010
2012 The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer discovery 49 22585860
2019 Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases. Clinical epigenetics 46 30832707
2019 The Schizophrenia Susceptibility Gene OPCML Regulates Spine Maturation and Cognitive Behaviors through Eph-Cofilin Signaling. Cell reports 41 31577955
2017 Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. Oncology letters 40 28693156
2016 Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer. Epigenetics 40 26890304
2015 OPCML is frequently methylated in human colorectal cancer and its restored expression reverses EMT via downregulation of smad signaling. American journal of cancer research 34 26175934
2007 Synaptic adhesion molecule OBCAM; synaptogenesis and dynamic internalization. Brain research 32 17658490
2018 The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. EMBO reports 30 29907679
2005 RAS-mediated epigenetic inactivation of OPCML in oncogenic transformation of human ovarian surface epithelial cells. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 30 16384911
2000 Expression of the IgLON cell adhesion molecules Kilon and OBCAM in hypothalamic magnocellular neurons. The Journal of comparative neurology 29 10888740
1996 A family of glycoproteins (GP55), which inhibit neurite outgrowth, are members of the Ig superfamily and are related to OBCAM, neurotrimin, LAMP and CEPU-1. Journal of cell science 28 9004047
2017 The Tumor-Suppressor Protein OPCML Potentiates Anti-EGFR- and Anti-HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer. Molecular cancer therapeutics 25 28775148
2015 DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 25 25652468
2006 Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer. Neuro endocrinology letters 25 17159813
1992 Opioid-binding cell adhesion molecule (OBCAM)-related clones from a rat brain cDNA library. Gene 24 1339369
1996 Characterization and tissue distribution of opioid-binding cell adhesion molecule (OBCAM) using monoclonal antibodies. Neurochemistry international 21 8740443
2018 Effect of luteolin on the methylation status of the OPCML gene and cell growth in breast cancer cells. Experimental and therapeutic medicine 20 30214542
2007 Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma. European journal of gynaecological oncology 19 18179137
1995 Cloning, sequencing and localization to chromosome 11 of a cDNA encoding a human opioid-binding cell adhesion molecule (OBCAM). Gene 16 7721093
2019 Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions. Nature communications 14 31316070
2006 [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma]. Ai zheng = Aizheng = Chinese journal of cancer 14 16764763
2000 Developmental expression of opioid-binding cell adhesion molecule (OBCAM) in rat brain. Brain research. Developmental brain research 14 10960687
2003 Polarized targeting of IgLON cell adhesion molecule OBCAM to dendrites in cultured neurons. Brain research 13 12850579
2020 LINC00619 restricts gastric cancer progression by preventing microRNA-224-5p-mediated inhibition of OPCML. Archives of biochemistry and biophysics 12 32359894
2020 Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers. Cancer gene therapy 12 32595215
2011 OPCML gene as a schizophrenia susceptibility locus in Thai population. Journal of molecular neuroscience : MN 12 21833655
2009 OBCAM, an immunoglobulin superfamily cell adhesion molecule, regulates morphology and proliferation of cerebral astrocytes. Journal of neurochemistry 11 19943852
2012 New roles opined for OPCML. Cancer discovery 10 22585855
2022 GPBAR1 preserves neurite and synapse of dopaminergic neurons via RAD21-OPCML signaling: Role in preventing Parkinson's disease in mouse model and human patients. Pharmacological research 9 36152741
2014 Gene-targeted deletion of OPCML and Neurotrimin in mice does not yield congenital heart defects. American journal of medical genetics. Part A 9 24616287
1999 Localization of opioid-binding cell adhesion molecule (OBCAM) in adult rat brain. Brain research 8 10526147
2020 Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer. Breast cancer (Tokyo, Japan) 7 33108608
2006 [Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 7 16733898
1997 Expression of opioid-binding cell adhesion molecule (OBCAM) and neurotrimin (NTM) in E. coli and their reactivity with monoclonal anti-OBCAM antibody. Neuroreport 7 9331906
2021 OPCML Exerts Antitumor Effects in Cholangiocarcinoma via AXL/STAT3 Inactivation and Rho GTPase Down-regulation. Cancer genomics & proteomics 6 34697068
2020 [Luteolin reverses OPCML methylation to inhibit proliferation of breast cancer MDA-MB-231 cells]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 6 32895125
2019 OPCML: A Promising Biomarker and Therapeutic Avenue. Trends in cancer 6 31421903
2024 Mechanisms of glutamate receptors hypofunction dependent synaptic transmission impairment in the hippocampus of schizophrenia susceptibility gene Opcml-deficient mouse model. Molecular brain 5 39420375
2024 The Risk Genes for Neuropsychiatric Disorders negr1 and opcml Are Expressed throughout Zebrafish Brain Development. Genes 4 38540422
1999 cDNA cloning of the CEPUS, a secreted type of neural glycoprotein belonging to the immunoglobulin-like opioid binding cell adhesion molecule (OBCAM) subfamily. Molecules and cells 4 10420985
1996 Expression of OBCAM-related cDNA clones in Cos 1 cells: evidence for a phosphatidylinositol linkage to the cell membrane. Brain research. Molecular brain research 4 8965653
2016 Effect of OPCML gene on the biological behavior of gastric cancer cell line AGS. Journal of biological regulators and homeostatic agents 3 27358143
2009 Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract. Reproduction (Cambridge, England) 2 19176311
2006 [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells]. Zhonghua fu chan ke za zhi 2 16762191
1995 Alteration of OBCAM conformation as a result of opioid receptor expression and opioid ligand treatment. Brain research 2 8581474
1990 Opioid-binding protein (OBCAM) is rich in beta-sheets. Journal of protein chemistry 2 2340074
2018 OPCML is hypermethylated in a subset of patients with metaplastic changes in their esophagus. Biomarker research 1 30555700
2026 Downregulation of OPCML is associated with activation of AKT signaling and aggressive phenotypes in glioblastoma cells. Frontiers in oncology 0 41561740
2025 Bioinformatic RNA-Seq Functional Profiling of the Tumor Suppressor Gene OPCML in Ovarian Cancers: The Multifunctional, Pleiotropic Impacts of Having Three Ig Domains. Current issues in molecular biology 0 40699804

Missed literature

Know a paper Affinage missed for OPCML? Flag it for the maintainers and the community.

No submissions yet.